Company profile: Phaxiam Therapeutics
1.1 - Company Overview
Company description
- Provider of bacteriophage-based therapies to combat antimicrobial-resistant bacterial infections, offering phage treatments, GMP individualized phage therapies (IPT), standardized phage therapies medicinal products (PTMP), a phage portfolio targeting Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa, an in vitro Phagogram test for phage susceptibility, and PhagoDAIR clinical trial.
Products and services
- Phage Therapies Medicinal Products (PTMP): Standardized medicinal-grade phage products engineered to treat antibiotic-resistant bacterial infections, addressing hospital-acquired pathogens such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa
- GMP Individualized Phage Therapies (IPT): GMP-compliant customized phage treatments crafted to target specific bacterial strains causing severe resistant infections, including Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa
- Phagogram Test: In vitro diagnostic phage-susceptibility assay enabling selection of effective bacteriophages against the infecting strain to guide targeted therapy for antibiotic-resistant bacterial infections
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Phaxiam Therapeutics
iCardiac
HQ: United States
Website
- Description: Provider of cardiac safety biomarkers and ECG-based markers for assessing the cardiac safety profile of drugs in development; offers Dynamic QTbtbsm, a suite of ECG-based cardiac safety markers, used in cardiac clinical trials by pharmaceutical, biotechnology, and medical device companies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iCardiac company profile →
Synchrogenix
HQ: United States
Website
- Description: Provider of strategic regulatory writing and related services for the pharmaceutical and biotech industry, offering regulatory strategy, consulting, and submissions support from preclinical to post-marketing; eCTD publishing and management; medical writing and scientific communications; clinical data transparency, anonymization and redaction; document quality and management; and GlobalSubmit eCTD software.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synchrogenix company profile →
Bioscience Advisors
HQ: United States
Website
- Description: Provider of consulting and database services focused on biopharma alliances, offering retained consulting services to companies; founded by Mark Edwards, who has been involved in negotiating and analyzing biopharma alliances since the mid-1980s.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bioscience Advisors company profile →
Vistin Pharma
HQ: Norway
Website
- Description: Provider of active pharmaceuticals and solid dosage forms focused on metformin, manufacturing and supplying metformin in various forms, including Metformin Hydrochloride (API) meeting purity and flow quality standards and Metformin Direct Compressible Premix for immediate-release tablet compression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vistin Pharma company profile →
Althea Technologies
HQ: United States
Website
- Description: Provider of contract manufacturing services to the pharmaceutical and biotechnology industries, offering gene expression analysis via eXpress Profiling, quantitative PCR testing, cGMP drug product filling in vials and syringes, and production of microbial-derived recombinant proteins and plasmid DNA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Althea Technologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Phaxiam Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Phaxiam Therapeutics
2.2 - Growth funds investing in similar companies to Phaxiam Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Phaxiam Therapeutics
4.2 - Public trading comparable groups for Phaxiam Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →